New patent expiration for United Therap drug ORENITRAM

Annual Drug Patent Expirations for ORENITRAM

Orenitram is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and two Paragraph IV challenges.

Drug patent litigation for ORENITRAM.

This drug has fifty-nine patent family members in eight countries.

The generic ingredient in ORENITRAM is treprostinil diolamine. One supplier is listed for this compound. Additional details are available on the treprostinil diolamine profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com